introduct
fluocinolon
acetonid
fa
intravitr
implant
mg
retisert
bausch
lomb
rochest
ny
usa
provid
sustain
releas
fa
directli
vitreou
caviti
prolong
period
time
purpos
studi
evalu
safeti
efficaci
fa
term
uveiti
compris
group
intraocular
inflammatori
condit
directli
indirectli
affect
iri
ciliari
bodi
choroid
collect
known
uveal
tract
well
retina
optic
nerv
vitreou
case
etiolog
uveiti
unknown
howev
associ
autoimmun
diseas
infect
viral
fungal
parasit
trauma
uveiti
result
signific
visual
impair
thought
account
case
total
blind
unit
state
us
develop
world
posterior
uveiti
account
estim
peopl
us
uveiti
sever
form
diseas
primari
caus
vision
loss
patient
uveiti
cystoid
macular
edema
cme
andor
cataract
cme
lead
caus
vision
loss
posterior
uveiti
treatment
aim
reduc
cme
therefor
effect
treatment
uveiti
corticosteroid
consid
mainstay
noninfecti
uveiti
treatment
howev
sinc
diseas
typic
chronic
natur
patient
often
requir
longterm
repeat
treatment
either
topic
system
corticosteroid
sever
case
uveiti
multipl
round
subtenon
intravitr
corticosteroid
inject
well
system
corticosteroid
may
necessari
potenti
complic
endophthalm
vitreou
hemorrhag
retin
detach
follow
use
repeat
intravitr
inject
substanti
system
corticosteroid
requir
high
dosag
achiev
therapeut
concentr
eye
associ
system
side
effect
includ
hypertens
hyperglycemia
increas
suscept
infect
immunosuppress
agent
effect
treatment
option
associ
seriou
potenti
lifethreaten
system
advers
event
ae
renal
hepat
failur
bone
marrow
suppress
thu
therapi
usual
reserv
patient
sever
uveiti
unrespons
corticosteroid
therapi
corticosteroidinduc
complic
multicent
random
doublemask
dosecontrol
safeti
efficaci
studi
two
fa
intravitr
implantson
contain
mg
mgin
patient
chronic
recurr
unilater
fa
implant
surgic
implant
procedur
describ
detail
elsewher
briefli
polym
one
week
postimplant
patient
discontinu
use
exist
therapi
ocular
inflamm
follow
consequ
patient
evalu
fluorescein
angiographi
screen
week
week
year
use
standard
protocol
macular
hyperfluoresc
evalu
mask
reader
describ
previous
three
type
comparison
util
studi
maximum
vitreou
haze
maximum
reduct
visual
acuiti
logarithm
minimum
angl
resolut
logmar
snellen
equival
consid
suffici
sever
count
analysi
medic
chart
lack
suffici
detail
determin
whether
preimplant
recurr
met
protocol
definit
preimplant
recurr
record
analysi
recurr
within
postimplant
period
defin
follow
increas
compar
baselin
number
ac
cell
attribut
condit
nipu
increas
compar
baselin
vitreou
haze
attribut
condit
nipu
deterior
bcva
baselin
least
logmar
attribut
condit
nipu
recurr
consid
observ
seen
record
studi
investig
wherea
consid
imput
subject
seen
within
week
final
schedul
visit
secondari
efficaci
outcom
evalu
use
fellow
nonimpl
eye
control
studi
eye
includ
rate
time
postimplant
recurr
uveiti
chang
bcva
area
cme
use
fluorescein
angiogram
proport
eye
requir
system
therapi
periocular
inject
control
inflamm
use
preimplant
comparison
group
data
secondari
efficaci
outcom
includ
observ
imput
recurr
data
applic
safeti
outcom
includ
intraocular
pressur
iop
len
opac
estim
use
len
opac
classif
system
loc
ii
visual
field
ocular
nonocular
ae
visual
acuiti
ophthalmoscop
examin
find
ophthalmol
ther
ocular
ae
defin
unexpect
ocular
condit
consid
investig
clinic
signific
includ
limit
iop
increas
requir
medic
increas
dosagefrequ
iop
mm
hg
month
postsurgeri
mm
hg
loss
line
visual
acuiti
baselin
last
schedul
visit
retin
tear
statist
analys
perform
use
sa
tabl
uveiti
recurr
rate
implant
eye
preand
postimplant
uveiti
recurr
rate
implant
eye
shown
tabl
kaplanmei
analysi
use
evalu
time
recurr
uveiti
implant
nonimpl
eye
fig
kaplanmei
analysi
implant
studi
eye
versu
nonimpl
fellow
eye
perform
patient
bilater
diseas
yield
similar
result
time
recurr
uveiti
significantli
longer
implant
eye
fellow
nonimpl
eye
data
shown
fa
intravitr
implant
reduc
need
adjunct
uveiti
treatment
proport
patient
requir
adjunct
treatment
control
inflamm
fa
implant
shown
tabl
visit
locf
mean
cme
mm
nonimpl
fellow
eye
dose
group
combin
mean
area
cme
fluctuat
comparison
made
entir
preimplant
period
postimplant
period
one
fellow
eye
fa
implant
group
prosthet
thu
sampl
size
fellow
eye
c
p
valu
year
preimplant
data
compar
year
postimplant
data
within
narrow
rang
postimplant
followup
period
area
cme
screen
similar
visit
approxim
mm
number
patient
experienc
reduct
area
cme
baselin
postimplant
present
tabl
mean
exposur
fa
day
implant
group
day
implant
group
treatmentemerg
ocular
ae
includ
periop
event
report
implant
studi
eye
fellow
nonimpl
eye
tabl
present
frequent
occur
ae
implant
studi
eye
nonimpl
fellow
eye
implant
dose
group
combin
among
frequent
observ
ocular
ae
report
implant
studi
eye
elev
iop
cataract
commonli
associ
ocular
steroid
use
frequent
report
ae
implant
eye
eg
eye
pain
hypotoni
conjunctiv
hemorrhag
hyperemia
appear
primarili
associ
surgeri
fellow
eye
frequent
observ
ocular
ae
decreas
visual
acuiti
cataract
format
eye
pain
part
due
uveit
inflamm
experienc
effect
tabl
rate
chang
len
opac
baselin
subcapsular
nuclear
visual
field
sensit
quantifi
mean
deficit
md
measur
decibel
db
